Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02013180 · OUTCOME

Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases

Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection · Source last updated 2019-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
ratio
Interval / dispersion
Inter-Quartile Range
Time frame
measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks

What was measured

Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer?

Groups in this outcome

Prostate Cancer

prostate adenocarcinoma in pathologic evaluation

Control

benign prostatic diseases in pathologic evaluation

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Prostate Cancer119
Control361

Reported measurements

Source class 1
Values in ratio · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Prostate Cancer150.8Not reported51.8264.1Not reported
Control239.6Not reported145.1357.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        51.8
        upper Limit
        264.1
        value
        150.8
      2. group Id
        OG001
        lower Limit
        145.1
        upper Limit
        357.7
        value
        239.6
denoms
  1. counts
    1. group Id
      OG000
      value
      119
    2. group Id
      OG001
      value
      361
    units
    Participants
description
Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer?
dispersion Type
Inter-Quartile Range
groups
  1. description
    prostate adenocarcinoma in pathologic evaluation
    id
    OG000
    title
    Prostate Cancer
  2. description
    benign prostatic diseases in pathologic evaluation
    id
    OG001
    title
    Control
param Type
MEDIAN
reporting Status
POSTED
time Frame
measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks
title
Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases
type
PRIMARY
unit Of Measure
ratio

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice